En

June 10-13, 2019Krakow, Poland

This biennial meeting is a key symposium in its field with traditionally around 300 participants, from industry and academia. The EFMC - ACSMEDI Medicinal Chemistry Frontiers Meeting attracts a highly targeted audience composed of experts in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, early toxicology, as well as chemical and pharmaceutical development. The scientific programme for this meeting will feature a plenary session, followed by sessions covering the latest advances in medicinal chemistry.

Topics

  • Adding AI to the Drug Discovery Tool Box
    Session Chair
    : Carolyn Dzierba (BRISTOL-MYERS SQUIBB, United States)
  • Advances in Protein Degradation Technologies
    Session Chair
    : Daniel Harki (UNIVERSITY OF MINNESOTA, United States)
  • Chemical Biology Tools & Target Engagement Technologies
    Session Chair
    : Edgars Suna (LATVIAN INSTITUTE OF ORGANIC SYNTHESIS, Latvia)
  • Genomics in Drug Discovery : Roles for Chemistry
    Session Chair
    : Terry Moore (UNIVERSITY OF ILLINOIS, United States)
  • GPCRs : a Discovery Powerhouse
    Session Chair
    : Yves P. Auberson (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Switzerland)
  • Matrix Metallo-Proteinases
    Session Chair
    : Krzysztof Józwiak (MEDICAL UNIVERSITY OF LUBLIN, Poland)
  • Multi-Targeted Drugs
    Session Chair
    : Andrzej Bojarski (INSTITUTE OF PHARMACOLOGY POLISH ACADEMY OF SCIENCES, Poland)
  • Opioid, Pain, Endo-Cannabinoid
    Session Chair
    : Katarzyna Kiec-Kononowicz (JAGIELLONIAN UNIVERSITY, Poland)
  • Targeted Covalent Inhibitors
    Session Chair
    : Anders Karlén (UPPSALA UNIVERSITY, Sweden)
Organised by:
  • European Federation of Medecinal Chemistry (EFMC)
  • Polish Society of Medicinal Chemistry (Poland)